Edition:
United States

Genomic Health Inc (GHDX.O)

GHDX.O on Nasdaq

31.24USD
25 Sep 2017
Change (% chg)

$0.26 (+0.84%)
Prev Close
$30.98
Open
$31.00
Day's High
$31.68
Day's Low
$30.73
Volume
148,378
Avg. Vol
110,477
52-wk High
$33.97
52-wk Low
$26.37

Latest Key Developments (Source: Significant Developments)

Genomic Health and Biocartis announce agreement to develop a breast cancer test
Wednesday, 13 Sep 2017 01:00am EDT 

Sept 13 (Reuters) - BIOCARTIS GROUP NV ::‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​.‍EXCLUSIVE AGREEMENT TO DEVELOP AN IVD VERSION OF ONCOTYPE DX BREAST RECURRENCE SCORE TEST ON BIOCARTIS' IDYLLA PLATFORM​.‍ONCOTYPE DX BREAST RECURRENCE SCORE TEST PLANNED FOR LAUNCH IN EUROPE BEGINNING WITH FRANCE AND GERMANY IN 2019​.‍AS PART OF AGREEMENT, GENOMIC HEALTH WILL MAKE A PAYMENT OF APPROXIMATELY $3.3 MILLION TO BIOCARTIS, WHICH IS EXPECTED TO BE EXPENSED IN Q3 OF 2017​.‍GENOMIC HEALTH CONTINUES TO EXPECT TO BE PROFITABLE FOR FULL YEAR 2017, EXCLUDING THESE TRANSACTION COSTS​.‍UPON COMMERCIALIZATION, GENOMIC HEALTH WILL MAKE ROYALTY PAYMENTS TO BIOCARTIS BASED ON NET SALES OF IVD TESTS DEVELOPED ON BIOCARTIS' IDYLLA PLATFORM​.  Full Article

Palmetto GBA issues positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test
Thursday, 24 Aug 2017 08:00am EDT 

Aug 24 (Reuters) - Genomic Health Inc :Palmetto GBA issued positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test.  Full Article

Genomic Health Q2 loss per share $0.08
Tuesday, 1 Aug 2017 04:05pm EDT 

Aug 1 (Reuters) - Genomic Health Inc :Genomic Health announces second quarter 2017 financial results and reports recent business progress.Q2 loss per share $0.08.Q2 revenue $85.5 million versus I/B/E/S view $86.1 million.Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Sees 2017 total revenue of between $345 to $355 million.Sees profit for full-year at either end of revenue range.FY2017 earnings per share view $0.02, revenue view $356.1 million -- Thomson Reuters I/B/E/S.  Full Article

Genomic Health Q1 revenue $84 million
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Genomic Health Inc ::Genomic Health announces first quarter 2017 financial results and reports recent business progress.Q1 loss per share $0.02.Q1 revenue $84 million versus I/B/E/S view $86.2 million.Q1 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Says international product revenue was $13.4 million in Q1 of 2017, compared with $10.4 million in Q1 of 2016.Says U.S. product revenue was $70.6 million in Q1 of 2017, compared with $70.5 million in Q1 of 2016.  Full Article

Genomic Health says may sell up to 13.7 mln shares
Thursday, 11 Aug 2016 05:34pm EDT 

Genomic Health Inc : Says may sell up to an aggregate of 13.7 million shares of common stock - SEC filing .Shares being offered by selling stockholders, co will not receive any proceeds from the sale.  Full Article

Genomic Health files for mixed shelf of up to $350 mln - SEC filing
Thursday, 11 Aug 2016 04:15pm EDT 

Genomic Health Inc : Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2b0l97v ) Further company coverage: [GHDX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Genomic Health posts Q2 loss per share $0.18
Tuesday, 2 Aug 2016 04:05pm EDT 

Genomic Health Inc : Q2 loss per share $0.18 . Q2 revenue $82 million versus $70.6 million . Is raising low end of both revenue and test guidance for full-year ending December 31, 2016 . Maintaining net loss guidance between $12 and $18 million at mid-point of revenue guidance, excluding items for 2016 . FY2016 earnings per share view $-0.45, revenue view $330.3 million -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-0.18, revenue view $81.3 million -- Thomson Reuters I/B/E/S . Raising total revenue to between $325 and $335 million for 2016 .Sees 2016 basic net loss per share of between $0.37 and $0.55.  Full Article

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

* ‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​